Drug Profile
PF 5230901
Alternative Names: PF-05230901; PF-5230901Latest Information Update: 18 Aug 2011
Price :
$50
*
At a glance
- Originator Pfizer
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cachexia
Most Recent Events
- 11 Aug 2011 Discontinued - Phase-I for Cachexia in USA (SC)
- 05 Aug 2011 Pfizer completes enrolment in its phase I trial for Cachexia in USA (NCT01262690)
- 30 Nov 2010 Phase-I clinical trials in Cachexia in USA (SC)